Survodutide vs Retatrutide

Survodutide wins for:

• Highest efficacy and speed in hepatic (liver) fat reduction; the standout compound for users focused on NAFLD or cleaning up after heavy oral cycles.
• Thermogenic effect profile; subjectively "warmer" and favored by users for visible visceral fat loss beyond just the scale.
• Slightly smoother titration and less dramatic heart rate increase relative to retatrutide at aggressive doses.

Retatrutide wins for:

• Absolute magnitude of fat loss; phase 2 data levels nearly 25% off at the top dose—strongest weight loss ever logged in a major trial.
• Broader receptor coverage (GLP-1, GIP, glucagon) offering comprehensive appetite suppression, metabolic enhancement, and maximum ceiling for physique-driven cuts.
• Clean once-weekly dosing, slightly longer half-life (6 days), and potential for breaking plateaus where users have adapted to semaglutide or tirzepatide.

Pick Survodutide if:

• The goal is rapid reversal of hepatic (liver) fat or post-cycle oral clean-up.
• Preference for a more pronounced thermogenic/"hot" effect with visible bias toward visceral fat loss.
• Seeking robust weight/fat loss without the absolute high-end GI and HR side effects seen with triple agonists.
• Users already tolerant to GLP-1 agonists but want to add a glucagon axis without going full triple.
• Monitoring for muscle loss is a priority and tolerance for gradual titration exists.

Pick Retatrutide if:

• The primary target is maximal, scale-crushing fat loss in the shortest timeline—sub-20% BW loss protocols.
• Plateaued on semaglutide or tirzepatide and want the next step up in both hunger suppression and metabolic drive.
• Willing to navigate a steeper GI and HR side effect profile to push further down below the original bodyfat set point.
• Stacking with TRT and focused on muscle retention while dropping fat as rapidly as current pharmacology allows.
• Looking for a protocol that plays well with mini-cuts, post-bulk, or aggressive physique prepping.